/
/
ASCO 2020: Are Myeloma Patients Getting the Right Vaccinations?
ASCO 2020: Are Myeloma Patients Getting the Right Vaccinations? image
ASCO 2020: Are Myeloma Patients Getting the Right Vaccinations?
Posted May 26, 2020

Vaccines are the first line of prevention for infectious diseases. This is key for myeloma patients because infection is a major cause of death in myeloma. Multiple myeloma patients are more at risk for infection due to the disease itself and potentially due to a depresssed immune system because of myeloma treatment.

Michael Thompson, MD, PhD of Advocate Aurora Health in collaboration with the Myeloma Crowd and the HealthTree platform published data at the ASCO 2020 conference showing real world data of up to 500 myeloma patients. Patients were asked about their vaccination status for a variety of vaccines. 

Have you ever been vaccinated in the last 5 years with a pneumococcal vaccine (PV)?

 

After you began myeloma treatment, did you ever receive the anti-Varicella Zoster Virus (VZV, shingles) vaccine?

 

In the last 3 flu seasons, have you received the influenza vaccine (FV)?

 

Were you (or are you currently) treated with anti-viral drugs?

 

Were you (or are you currently) treated with antibiotic bactrim?

 

Were you (or are you currently) treated with levofloxacin prior to stem cell transplant or at the beginning of your MM therapy?

Dr. Thompson found that myeloma patients in HealthTree had high use of the flu and pneumonia vaccines when compared to healthy individuals in a large system and global registry

The majority of myeloma patients did not receive a shingles vaccine, which was surprising. A few patients recieved the live shingles vaccine (which is not recommended for myeloma patients). Patients should ask their doctor if they should receive the dead version of the shingles vaccine. 

The antibiotic levofloxacin was used in a minority of patients. 

The use of anti-viral medications was common, but not universal.

Dr. Thompson notes that using an online portal like HealthTree can help investigators learn from real-world data in the patient community and result in the development of new hypotheses and research questions. 


First Author: Michael A. Thompson, MD, PhD, FASCO

Meeting: 2020 ASCO Virtual Scientific Program

Session Title: Publication Only: Hematologic Malignancies—Plasma Cell Dyscrasia

Track: Hematologic Malignancies—Plasma Cell Dyscrasia, Subtrack: Multiple Myeloma, Abstract #: e20567

Citation: J Clin Oncol 38: 2020 (suppl; abstr e20567), DOI: 10.1200/JCO.2020.38.15_suppl.e20567

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811